Clinical observation on 50 cases of chronic hepatitis B virus infection patients treated with entecavir

Objective To evaluate the early efficacy of entecavir(ETV) for patients of chronic hepatitis B virus(HBV) infection and improve the treatment level.Methods The patients were divided into HBeAg positive group(30 cases) and HBeAg negative group(20 cases) according to the results of HBV serology,and were administered with ETV and liver protectant drugs.After 2 weeks,HBV DNA level(measured by quantitative PCR) and liver function were tested.Results Significant reduction of HBV DNA could be detected by PCR assay after 2 weeks of treatment,the mean reduction in serum HBV DNA from baseline to week 2 were 3.005 log10 in HBeAg positive group and 3.410 log10 in HBeAg negative group(P0.001).Undetectable serum HBV DNA levels were observed in 1 case(HBeAg-positive group) and 8 case(HBeAg-negative group).There is no adverse event related to the ETV treatment.Conclusions ETV is a potent and selective guanosine analogue with significant activity against HBV.It is anticipated that longer duration of therapy will result in significant clinical benefit.